Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,963 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,963 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Open enrollment, early-phase tilt
HIV Infections has 615 registered US clinical trials, 56 of them open to new participants right now, about 9% of the total.
- 56
- recruiting participants now
- 9%
- of trials open to enrollment
- 92
- in Phase 3-4 (later-stage)
- 195
- top sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Corpus placement: #7 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 3 of 13
Parents Matter!: Interventions to Promote Effective Parent-Child Communication
Centers for Disease Control and Prevention
NCT00137943
The SOLVE-IT National Randomized Trial
University of Southern California
NCT00653991
The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs
Boehringer Ingelheim
NCT00002368
Piloting At-birth Point of Care HIV Testing Strategies in Kenya
University of Kansas Medical Center
NCT03435887
A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000922
A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT00000751
A Registry of Tuberculosis Cases in the CPCRA
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000785
Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00006396
Comparison of ddI Versus Zidovudine in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000979
The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000960
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
Yale University
NCT00628771
Botswana TDF/FTC Oral HIV Prophylaxis Trial
Centers for Disease Control and Prevention
NCT00448669
IMPAACT P1074: Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
NCT01061164
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001038
Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection
ViiV Healthcare
NCT03400293
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00013520
The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001030
Expanded Access Program for Maraviroc At Multiple Centers
ViiV Healthcare
NCT00426660
Study of Provider Computer Alerts Designed to Improve Delivery of HIV Care
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00678600
Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic
The Miriam Hospital
NCT00947271
Training Community Members to Deliver HIV Prevention Programs to Urban Youth
Icahn School of Medicine at Mount Sinai
NCT00859144
A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000919
Effects of Two Anti-HIV Drug Regimens on HIV Transmission Risk Behavior Among SMART Study Participants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00386035
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
Gilead Sciences
NCT01780506
HIV Prevention Program for African American Teen Males
Richard Crosby
NCT00849823
eTest: Real-time, Remote Monitoring System for Home-based HIV Testing Among High-risk Men Who Have Sex With Men
Brown University
NCT03654690
Psychiatric Problems in Children and Adolescents Infected With HIV at Birth
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
NCT00100542
Seek, Test, Treat, Retain: An Integrated Jail-Prison-Community Model for Illinois
University of Illinois at Chicago
NCT01852877
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
Pharmacia
NCT00002032
A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000671
A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs
Johns Hopkins Bloomberg School of Public Health
NCT00183456
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences
NCT01095796
TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
Tibotec Pharmaceuticals, Ireland
NCT00543725
HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)
Emory University
NCT03763942
Evaluation of Enrollment, Dynamics of Care and Patient Outcomes in the NYS Medicaid HIV Special Needs Plans
Memorial Sloan Kettering Cancer Center
NCT00577811
A Comparison of Two Tests for Anti-HIV Drug Resistance
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00006490
A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
Merck Sharp & Dohme
NCT00002155
Internet-Based Sexual Health Education for Middle School Native American Youth
The University of Texas Health Science Center, Houston
NCT01303575
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
Bristol-Myers Squibb
NCT00035932
A Study of Anal Cancer Development in HIV Infected People
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00107679
A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001104
Reducing HIV & Domestic Violence Risk in Women Offenders
Multnomah County Health Department
NCT00289939
T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs
Hoffmann-La Roche
NCT00008528
Improving Health Outcomes in Young Cisgender Men and Transgender Women (mLab App)
Rebecca Schnall, RN, MPH, PhD
NCT03803683
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001082
A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
Schering-Plough
NCT00002399
A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001084
Positive Choice: Prevention for Positive Health
National Institute on Drug Abuse (NIDA)
NCT00447707
HIV Prevention Intervention for People Living With HIV/AIDS
University of Connecticut
NCT01061021
Adult Sexual Risk Behavior Among Women With a History of Childhood Sexual Abuse
Syracuse University
NCT00653575
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for HIV Infections right now
56 recruiting of 615 indexed (9% open).
Phase mix: 92 late (III/IV) vs 266 early (I/II) (early-phase heavy).
Top sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (195 trials), 9 others listed. 50 shown below, recruiting first. #7 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for HIV Infections?
PlainTrial tracks 615 US clinical trials for HIV Infections, of which 56 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for HIV Infections?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.